In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

This article covers key health news including Primary Health Properties securing a takeover bid for Assura, Novo Nordisk's ...

Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

Scientists have uncovered a hidden molecule in DNA that helps control fat storage, offering hope for a new kind of obesity treatment.